Cases Of Vulvovaginal Candidiasis Research Articles

Changing Virulence Factors among Vaginal Non-albicans Candida species

Background: Vulvovaginal candidiasis (VVC) is caused by overgrowth of Candida species in the female lower genital tract and most commonly caused by Candida albicans. The production of various virulence factors may attribute to their pathogenicity. Hence, this study was aimed to determine the production of various virulence factors of Candida spp. causing VVC. Materials and Methods: A total of 51 Candida spp. were isolated prospectively from 50 patients among 211 clinically suspected cases of VVC. The haemolytic activity, biofilm production, proteinase activity, phospholipase activity and esterase activity were detected by standard methods. Statistical analysis was performed using OpenEpi version 3.01. Results: Haemolytic activity was observed in 42 Candida isolates (82.4%), biofilm activity in 21 Candida isolates (41.2%), proteinase and esterase activity in 19 Candida isolates (37.3%) each and phospholipase activity in 15 Candida isolates (29.4%). Phospholipase activity was observed in all of the C. albicans strains, whereas all strains of Candida krusei were able to produce biofilm. All strains of Candida parapsilosis and 87% strains of Candida glabrata were haemolytic. Five of the eight C. glabrata strains were found to produce strong proteinase (Prz score ≤0.63). About 30.4% strains of C. glabrata and 20% strains of C. krusei were found to be positive for esterase activity. This is one of the few studies which revealed esterase activity among C. glabrata and C. krusei strains. Conclusions: This study highlighted that there is a change in the virulence factors among the non-albicans Candida species, especially C. glabrata strains which were haemolytic and produce strong proteinase activity and esterase activity. It may be one of the explanation of the most common causative agent of VVC in our study. Multicentric studies from this area might be required to get a more generalised conclusion.

PREVALENCE OF VULVOVAGINAL CANDIDIASIS IN SEXUALLY ACTIVE FEMALES WITH ANTIFUNGAL SUSCEPTIBILITY PATTERNS OF THE ISOLATES

Introduction: Vulvovaginal candidiasis (VVC) is the most common fungal infection of lower genital tract of females. It is an important cause of morbidity in young women due to its increasing incidence and is considered as an important public health problem worldwide. In recent years there has been a change in the trend of infections caused by non-albicans Candida species and anti-fungal susceptibility patterns. This study was carried out to assess the prevalence, potential risk factors and detect the antifungal susceptibilities of the isolates. Methods: A prospective study was conducted in a tertiary health centre of southern Odisha from January 2016 to December 2017and included 240 clinically diagnosed cases of VVC in the reproductive age group presenting with curdy white discharge with or without pruritus, burning, or dysuria. After getting an informed consent and brief history, vaginal swabs were collected and microscopic examination, culture and antifungal susceptibility were done. Results: Most common age group affected by VVC belonged to 26-35 years and majority of the cases were from rural areas. A total of 87 Candida species (36.3%) and, 4 Trichosporon asahii were isolated. Candida albicans was the most common isolate (52), followed by Candida glabrata. Most of the isolates were sensitive to clotrimazole (90.1%) followed by fluconazole (83.5%). Conclusion: The prevalence of VVC in our study was found to be 36.3%. Low socioeconomic status, low education, oral contraceptive pill users and Diabetes were the common predisposing factors. The most common agent causing VVC was Candidia albicans followed by Candida glabrata. Most of the yeasts isolated were sensitive to Clotrimazole followed by fluconazole. Keywords: Candida; Vulvovaginal candidiasis; Antifungal susceptibility.

In vitro activity of Spirulina platensis water extract against different Candida species isolated from vulvo-vaginal candidiasis cases.

The high incidence of vulvo-vaginal candidiasis, combined with the growing problems about azole resistance and toxicity of antifungal drugs, highlights the need for the development of new effective strategies for the treatment of this condition. In this context, natural compounds represent promising alternatives. The cyanobacterium Spirulina platensis, a blue-green alga, exhibits antimicrobial activities against several microorganisms. Nevertheless, only few data about the antifungal properties of Spirulina platensis are available and its potential toxic effects have not been largely investigated.The aim of this study was to evaluate the in vitro activity of a fully-characterized water extract of Spirulina platensis against 22 strains of Candida spp. Prior to considering its potential topical use, we both investigated whether the extract exerted target activities on guinea pig uterine smooth muscle, and the impact of Spirulina platensis on the dominant microorganisms of the vaginal microbiota (i.e., lactobacilli), in order to exclude possible adverse events. By means of a broth microdilution assay, we found that the microalga extract possesses good antifungal properties (MIC: 0.125–0.5 mg/ml), against all the Candida species with a fungicidal activity. At the concentrations active against candida, Spirulina platensis did not modify the spontaneous basic waves pattern of uterine myometrium as underlined by the absence of aberrant contractions, and did not affect the main health-promoting bacteria of the vaginal ecosystem. Finally, we evaluated the selectivity index of our extract by testing its cytotoxicity on three different cell lines and it showed values ranging between 2 and 16.Further in vivo studies are needed, in particular to evaluate the use of control-release formulations in order to maintain Spirulina platensis concentrations at anti-Candida active doses but below the toxic levels found in the present work.

Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital.

Vulvovaginal Candidiasis (VVC) is a common medical health problem of adult women. It is most commonly caused by Candida albicans. But there is a change in fungal profile. Sabouraud's Dextrose Agar (SDA) is the most common culture medium used where mixed fungal infection may be missed. It can be detected easily by using chromogenic culture medium. To know the fungal profile of vulvovaginal candidiasis using Candida CHROMagar and antifungal susceptibility pattern in patients attending tertiary care hospital. Culture confirmed cases of VVC presented at Department of Obstetrics and Gynaecology of Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, from July 2015 to December 2015 were included in the cross-sectional study. Two high vaginal swabs were collected and inoculated on SDA and Candida CHROMagar (Hi-Media, Mumbai, India). After overnight incubation the colonies were counted and colour of the colonies were recorded from Candida CHROMagar. Candida spp. were identified by sugar fermentation and assimilation tests and other conventional tests. Antifungal susceptibility tests were performed by the disc diffusion method using fluconazole (25 μg) and voriconazole (1μg) as per the Clinical and Laboratory Standards Institute (CLSI - M44-A2) guidelines. A total of 50 culture confirmed (23.7%) cases were detected from 211 clinically suspected VVC cases. Candida glabrata (45.1%) was the most common isolate, followed by Candidatropicalis (23.5%), Candida albicans (17.6%), Candida krusei (9.8%) and Candida parapsilosis (3.9%). One mixed infection of C. glabrata and C. albicans was identified on Candida CHROMagar. Mixed fungal infection was observed in 2% of positive culture and 0.5% of VVC cases. The antifungal susceptibility testing revealed that 15.7% and 9.8% isolates of Candida spp. were resistant and Susceptible Dose Dependent (S-DD) respectively to fluconazole. The increase resistant against fluconazole was because of increased isolation of C. glabrata strains. All strains of Candida spp. were susceptible to voriconazole. C. glabrata was the most common causative agent of VVC in a tertiary care hospital. Chromogenic culture medium facilitates detection of mixed fungal infection. In vitro susceptibility testing should be used to guide the treatment especially in cases of non-albicans Candidiasis.

TRATAMENTO DA CANDIDÍASE VULVOVAGINAL E NOVAS PERSPECTIVAS TERAPÊUTICAS: UMA REVISÃO NARRATIVA

Introdução: A candidíase vulvovaginal (CVV) é um processo infeccioso do trato geniturinário inferior feminino causada pelo fungo Candida. No Brasil, é o segundo diagnóstico mais comum em ginecologia e tem ocasionado preocupação dos profissionais da saúde devido ao crescente número de casos recorrentes. A dificuldade na abordagem terapêutica da CVV aponta para a relevância do desenvolvimento de estudos que abordem as atuais terapias utilizadas para esta infecção e suas limitações, atentando os profissionais da área a desenvolver a visão crítica acerca do tema e buscar modificações no manejo clínico. Objetivo: Este estudo visa descrever o panorama atual dos tratamentos da CVV e as novas perspectivas terapêuticas. Estratégia Metodológica: Foi desenvolvida uma revisão de literatura contendo artigos em língua inglesa e portuguesa acerca dos atuais tratamentos existentes para CVV e possíveis perspectivas terapêuticas. Resultados: Nota-se que os casos de CVV, principalmente os recorrentes, têm apresentado limitação na resposta aos tratamentos medicamentosos atuais e por isto há uma crescente busca por inovações terapêuticas. Dentre as novas possibilidades, o Diodo Emissor de Luz (LED) azul 405 nm é uma possível modalidade de tratamento, no entanto, necessita-se de mais estudos que comprovem sua eficácia. Conclusão: A terapia antifúngica atual tem apresentado limitações, principalmente nos casos de recorrência e isto fortalece a necessidade de busca de novas modalidades terapêuticas que sejam capazes de tratar o processo infeccioso inibindo os mecanismos de resistência do microorganismo.

Relationship of HPV infection and BV, VVC, TV: a clinical study based on 1 261 cases of gynecologic outpatients

Objective: To Explore the relationship between HPV infection and bacterial vaginosis(BV), vulvovaginal candidiasis(VVC), and trichomonal vaginitis(TV). Methods: Clinical data from 1 261 gynecologic outpatients who underwent the vaginal microecology and HPV type detection during June 2015 to December 2015 were collected and analyzed in the First Affiliated Hospital of Xi'an Jiaotong University. Results: In 1 261 patients, 328 cases infected with HPV, infection rate was 26.01%(328/1 261); vaginal infectious disease in 328 cases of HPV infections were 219 cases(66.8%, 219/328), vaginal infectious diseases in 933 cases of HPV uninfected were 503 cases(53.9%, 503/933), incidence of vaginal infectious disease in HPV infected patients was higher than that in HPV uninfected patients(χ2=5.87, P=0.01). 142 cases of BV had 54 cases infected with HPV(38.0%, 54/142), 296 cases of intermediate type BV had 88 cases infected with HPV(29.7%, 88/296), 231 cases of normal vaginal microecology had 51 cases infected with HPV(22.1%, 51/231), 99 cases of VVC had 15 cases infected with HPV(15.2%, 15/99), 2 patients with TV had 0 cases infected with HPV(0/2), HPV infection rate in BV, intermediate type BV patients were significantly higher than normal patients(P<0.05), while there were no statistical differences among VVC, TV and normal patients(P>0.05). The intensity of HPV infection were positively correlated with BV, intermediate type BV(OR=2.17, 95% CI: 1.37-3.43, P<0.01; OR=1.49, 95% CI: 1.00-2.22, P= 0.04); while, VVC, TV were uncorrelated with HPV infection(all P>0.05). Conclusions: BV, intermediate type BV are positively correlated with HPV infection, especially for the high-risk HPV. VVC and TV are not correlated with HPV infection.

Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus type 1 infected women in rural KwaZulu-Natal, South Africa.

Introduction. We sought to determine the association between HIV-induced immunosuppression, virologic correlates, and vulvovaginal candidiasis (VVC). Methods. This is a retrospective cohort study, where HIV infected and uninfected women were studied with VVC being the primary outcome. Ninety-seven HIV-infected and 101 HIV-uninfected women were enrolled between June and December 2011. Cases of VVC were confirmed. HIV RNA load was determined by RT-PCR and CD4 counts were obtained from medical records. Results. Fifty-two of 97 (53.6%) HIV-infected and 38/101 (37.6%) HIV-uninfected women were diagnosed with VVC (P = 0.032). The relative risk for VVC amongst HIV-infected patients was 1.53 (95% CI: 1.04–2 P = 0.024). Cases of VVC increased at CD4+ T cell count below 200 cells/mm3 (P < 0.0001) and plasma HIV RNA load above 10 000 copies/mL (P < 0.0001). VVC was associated with increased genital shedding of HIV (P = 0.002), and there was a linear correlation between plasma HIV load and genital HIV shedding (r = 0.540; R 2 = 0.292; P < 0.0001). Women on HAART were 4-fold less likely (P = 0.029) to develop VVC. Conclusion. CD4 counts below 200 cells/mm3 and plasma HIV loads ≥10 000 copies/mL were significantly associated with VVC.

Comparison Between Virulence Factors of Candida albicans and Non-Albicans Species of Candida Isolated from Genitourinary Tract.

Candida spp. is frequently isolated from cases of vulvovaginal candidiasis and catheter associated UTI. C.albicans is the most frequently isolated species but non-albicans species of candida are gaining clinical significance. To compare the virulence factors like biofilm production, phospholipase and hemolytic activity in C.albicans with that of non albicans species of candida isolated from urogenital tract. Vaginal swabs and urine samples received in Microbiology laboratory during one year period were processed by standard methods. The candida isolates were speciated and biofilm production, phospholipase and hemolytic activity were studied in them. Statistical analysis was performed using SPSS version 11.5. Out of the 3001 urine samples processed 41 (1.3%) were positive for candida, out of 293 high vaginal swabs 41(14%) were positive for candida. C.albicans was the most prevalent isolate followed by C.tropicalis, C.glabrata and C.krusei. Out of 40 C.albicans strains, 22 (55%) produced biofilm, 39 (97.5%) produced hemolysin and 21 (52.5%) produced phospholipase. Out of 42 strains of non albicans species of candida, 19 (45%) produced biofilm, 41(97.6%) hemolysin and 5 (12%) produced phospholipase. Phospholipase production was better in C.albicans in comparison toother species of candida. There was no statistically relevant difference between hemolysin and biofilm production by C.albicans and non albicans strains of candida.

Comparison of Enzymatic Method Rapid Yeast Plus System with RFLP-PCR for Identification of Isolated Yeast from Vulvovaginal Candidiasis.

To compare two identification methods, i.e., restriction fragment length polymorphism (RFLP)-PCR analysis and enzymatic method Rapid TM Yeast Plus System to identify different species causing vulvovaginal candidiasis (VVC). Vaginal discharges of women who had attended the gynecology outpatient clinic of Mobini Hospital in Sabzevar, Iran were collected using cotton swabs and were cultured on Sabouraud dextrose agar. Isolated yeasts were identified by germ-tube testing and Rapid TM Yeast Plus System (Remel USA). For molecular identification, the isolated DNA was amplified with ITS1 and ITS4 universal primers and PCR products digested with the enzyme HpaІІ followed by agarose gel electrophoresis. Epidemiological and clinical features of women with respect to identified species were also evaluated. Out of 231 subjects enrolled, 62 VVC cases were detected. The isolated species were identified as follows: Candida albicans, 24 (38.7%), C. glabrata, 15 (24.2%), C. kefyr, 13 (21.0%) C. krusei, 9 (14.5%), and Saccharomyces cerevisiae, 1 (1.6%) by RFLP-PCR method; whereas findings by Rapid TM Yeast Plus System were C. albicans, 24 (38.7%), C. glabrata, 5 (8%), C. kefyr, 11 (17.7%) C. krusei, 2 (3.2%), S. cerevisiae, 9 (14.5%), and C. tropicalis, 6 (9.6%) as well as other nonpathogenic yeasts, 4 (6.9%). Statistical comparison showed that there is no significant difference in identification of C. albicans by the two methods; although, in this study, it was not true about other species of yeasts. A correlation between clinical and laboratory findings is important as it enables us to administer an appropriate treatment on time.

Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species

Vulvovaginal candidiasis (VVC), particularly the recurrent form, remains an intractable problem for clinicians, microbiologists, and patients. It is essential to confirm the clinical diagnosis by mycological methods and avoid empirical therapy. The recovery of yeast in fungal culture, such as on Sabouraud dextrose agar, remains the gold standard for diagnosis. In this investigation, we examined 474 participants, including 122 (25.7%) with acute VVC cases, 249 (52.5%) who had recurrent VVC (RVVC) cases, and 103 (21.7%) healthy controls. We also administered a questionnaire to obtain information on patient lifestyle and medical, gynecological, and sexual history. In addition, we compared the performance of chromID Candida agar (CAN2) to CHROMagar Candida (CAC) and Sabouraud dextrose agar with gentamicin and chloramphenicol (SGC2). The yeasts were identified by conventional methods including the germ tube test, microscopic morphology on cornmeal-Tween 80 agar, and the commercial API 20C AUX system. We detected yeasts in 60 of 122 (49.2%) patients with acute VVC cases, 110 of 249 (44.2%) with RVVC cases, and in 35 of 103 (34%) healthy controls (P = 0.07). A total of 205 samples were found to be positive for fungi (43.2%), of which 176 (85.9%) were monofungal, and 29 (14.1%) were polyfungal. In addition, 198 of these samples (96.6%) were positive on CAN2, 195 (95.1%) on CAC, 189 (92.2%) on SGC2, and 183 (89.3%) samples on all three (P = 0.17). The 234 yeast isolates recovered were C. albicans (n = 118), C. glabrata (n = 82), C. kefyr (n = 11), C. krusei (n = 9), C. lipolytica (n = 3), C. colliculosa (n = 2), C. parapsilosis (n = 2), C. pelliculosa (n = 2), C. tropicalis (n = 2), and other species of Candida (n = 3). Of the 29 polyfungal populations, 28 (96.6%) were detected in CAN2, 25 in (86.2%) CAC, and 25 (86.2%) on both (P = 0.35). Notably, we detected the high predominance of C. albicans+C. glabrata (86.2%) in polyfungal populations. Briefly, the detection of C. albicans after 24 h of incubation was easier on CAN2 (64.4%) than on CAC (25.4%). This study showed that CAN2 is a rapid and reliable medium for immediate identification of C. albicans and for detecting polyfungal populations in vaginal specimens. We observed that the use of antibiotics, intrauterine devices, as well as, perineal laceration, short anovaginal distance (< 3 cm), and genital epilation in common areas are predisposing factors for RVVC (P < 0.001). In addition, we detected that the use of menstrual pad, using an (IUD), and having a history of childbirth increased the risk of both acute and recurrent VVC (P < 0.01), whereas the use of a daily pad and walking daily significantly decreased the risk of both acute and recurrent VVC (P < 0.01).

Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006

To determine the clinical characteristics of vulvovaginal candidiasis (VVC), the Candida species involved and the antifungal susceptibility of Candida species isolated from patients with VVC. Candida organisms were cultured from samples obtained from patients who presented with VVC to the Gynecology Department, Peking University Shenzhen Hospital. Antifungal susceptibility testing was performed using a commercial agar diffusion test. Of the 1,070 cases of VVC reported in this study, 36.5% were uncomplicated VVC, and 63.5% were complicated VVC. Twenty-four patients were identified as having two species of Candida. Candid albicans alone was isolated from 89.5% of cases (n = 958). Candida glabrata was isolated from 85 cases (7.9%), Candida tropicalis from 10 (0.9%), Saccharomyces cerevisiae from eight (0.7%), Candida parapsilosis from six (0.6%), Candida famata from two (0.2%), and Candida krusei from one case (0.1%). All isolates of Candida albicans were susceptible to nystatin. The resistant rate of Candida albicans to azole agents was 0-4.9%. Candida albicans was the predominant Candida species isolated from this series of patients with VVC. Resistance of vaginal Candida albicans isolates to antifungal agents was infrequent.

Current Treatment Options for Vulvovaginal Candidiasis

For practitioners, selecting successful therapy for vulvovaginal candidiasis is anything but trivial. The dominant problem; however, lies not with selecting the correct antimycotic agent, but with making the correct diagnosis and not treating non-yeast infections and noninfections as yeast-induced. Moreover, not all cases of vulvovaginal candidiasis are equal and practitioners owe patients the obligation of selecting appropriate therapy based upon the specific type and severity of vulvovaginal candidiasis. Uncomplicated candidiasis is readily treated with short-term oral or topical therapy, whereas complicated candidiasis needs additional strategies using the plethora of therapies available. Problematic refractory cases still abound and the pipeline for new, more potent antifungal agents is largely empty. Management strategies for complicated Candida vaginitis are discussed.